Foster Victor Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX

Key Points

• Foster Victor Wealth Advisors acquired a new stake in Royalty Pharma (RPRX) of 180,657 shares in Q4, valued at about $7.145 million.
• Insider selling has been significant: EVP Marshall Urist sold 20,000 shares and CFO Terrance P. Coyne sold 114,954 shares, with insiders selling 477,496 shares (~$20.4M) over the past 90 days; insiders own 18.90% of the stock while institutions hold 54.35%.
• Analyst sentiment is mostly positive (six Buys, average price target $49); RPRX reported an EPS beat of $1.46 vs. $1.33 but revenue missed ($622M vs. $840M), and the stock carries a market cap of about $28.16B with a P/E of 36.16.

Foster Victor Wealth Advisors LLC acquired a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 180,657 shares of the biopharmaceutical company's stock, valued at approximately $7,145,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Financiere des Professionnels Fonds d investissement inc. acquired a new position in shares of Royalty Pharma in the 3rd quarter valued at about $933,000. Nordea Investment Management AB lifted its stake in shares of Royalty Pharma by 18.3% in the 3rd quarter. Nordea Investment Management AB now owns 775,999 shares of the biopharmaceutical company's stock valued at $27,137,000 after purchasing an additional 120,004 shares during the period. World Investment Advisors acquired a new position in shares of Royalty Pharma in the 3rd quarter valued at about $1,702,000. Generali Asset Management SPA SGR lifted its stake in shares of Royalty Pharma by 7,752.8% in the 3rd quarter. Generali Asset Management SPA SGR now owns 34,081 shares of the biopharmaceutical company's stock valued at $1,202,000 after purchasing an additional 33,647 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Royalty Pharma by 28.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 140,131 shares of the biopharmaceutical company's stock valued at $4,944,000 after purchasing an additional 31,045 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RPRX. TD Cowen reissued a "buy" rating on shares of Royalty Pharma in a research note on Friday, February 27th. UBS Group raised Royalty Pharma from a "neutral" rating to a "buy" rating and set a $49.00 price objective on the stock in a research note on Friday, January 30th. Wall Street Zen downgraded Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. Morgan Stanley boosted their price objective on Royalty Pharma from $61.00 to $63.00 and gave the company an "overweight" rating in a research note on Friday. Finally, Weiss Ratings raised Royalty Pharma from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, February 12th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $49.00.

Insider Buying and Selling

In related news, EVP Marshall Urist sold 20,000 shares of the company's stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $39.52, for a total transaction of $790,400.00. Following the transaction, the executive vice president directly owned 40,000 shares of the company's stock, valued at approximately $1,580,800. This represents a 33.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Terrance P. Coyne sold 114,954 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total value of $4,924,629.36. Following the completion of the sale, the chief financial officer directly owned 23,972 shares of the company's stock, valued at approximately $1,026,960.48. This trade represents a 82.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 477,496 shares of company stock worth $20,408,425. 18.90% of the stock is owned by company insiders.

Royalty Pharma Stock Up 0.8%

RPRX stock opened at $48.82 on Wednesday. The stock's 50 day simple moving average is $46.16 and its 200 day simple moving average is $41.31. Royalty Pharma PLC has a fifty-two week low of $31.58 and a fifty-two week high of $49.06. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40. The company has a market cap of $28.16 billion, a P/E ratio of 36.16, a price-to-earnings-growth ratio of 3.09 and a beta of 0.39.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The business had revenue of $621.99 million for the quarter, compared to the consensus estimate of $839.97 million. On average, research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.